Loading...
Please wait, while we are loading the content...
Similar Documents
Mediterranean Diet and Naltrexone/Bupropion Treatment for Weight Loss in Overweight and Obese Breast Cancer Survivors and Non-Cancer Participants: A Pilot Randomized Controlled Trial
| Content Provider | Scilit |
|---|---|
| Author | Cho, A-Ra Choi, Won-Jun Kwon, Yu-Jin Lee, Hye Sun Ahn, Sung Gwe Lee, Ji-Won |
| Copyright Year | 2020 |
| Abstract | Introduction: The objective of this pilot randomized controlled trial was to investigate the combined effect of a Mediterranean diet and naltrexone/bupropion treatment on body weight, metabolic parameters, and quality of life in overweight or obese breast cancer survivors. Methods: Forty-four breast cancer survivors were randomly assigned to receive the Mediterranean diet plus naltrexone/bupropion medication (breast cancer survivor MeDiet+NB group) or the Mediterranean diet alone (breast cancer survivor MeDiet-only group). Twenty-eight age-matched non-cancer patients were instructed to consume the Mediterranean diet plus naltrexone/bupropion medication (non-cancer MeDiet+NB group). After the 8-week intervention, changes in body weight, metabolic parameters, nutrient intake, and quality of life of the three groups were assessed. Results: Significant weight loss of 2.8 kg was noted for the breast cancer survivor MeDiet+NB group, 1.8 kg for the breast cancer survivor MeDiet-only group, and 2.5 kg for the non-cancer MeDiet+NB group after 8 weeks (P < 0.05 versus baseline by Wilcoxon’s signed-rank test). All three groups also exhibited significantly lower fasting glucose, insulin, and homeostasis model assessment of insulin resistance levels (P < 0.05). Quality of life as assessed by self-reported questionnaires showed improvement in all participants (P < 0.05). However, there were no significant differences of changes in body weights, metabolic parameters, and quality of life among the three groups or between the MeDiet+NB and MeDiet-only groups. Conclusion: We found that the Mediterranean diet, with or without naltrexone/bupropion treatment, facilitates weight loss, improves metabolic parameters, and increases quality of life. The combination of the Mediterranean diet with naltrexone/bupropion treatment did not produce superior changes when compared to the Mediterranean diet alone. Trial Registration: This trial was retrospectively registered on 10 July 2018 as NCT03581630 at ClinicalTrials.gov (https://clinicaltrials.gov/ct2/show/NCT03581630). |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7532917/pdf https://www.dovepress.com/getfile.php?fileID=61941 |
| Ending Page | 3335 |
| Page Count | 11 |
| Starting Page | 3325 |
| ISSN | 11787007 |
| DOI | 10.2147/dmso.s269237 |
| Journal | Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy |
| Volume Number | 13 |
| Language | English |
| Publisher | Informa UK Limited |
| Publisher Date | 2020-09-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Integrative and Complementary Medicine Womens Studies Mediterranean Diet Naltrexone/bupropion Obesity Breast Cancer Survivors |
| Content Type | Text |
| Resource Type | Article |
| Subject | Internal Medicine Pharmacology |
